CRO/Sponsor

No one involved in clinical research is ever quite satisfied with the status quo.

There is a misalignment of experiences, expectations, and beliefs among subjects, investigators, sponsors, and service providers.

Systemized knowledge: experience, insight, and predictive modeling deliver successful enrollment.

Through digital signage, sponsors hope to increase enrollment in trials.

An intelligence-driven end-to-end approach defines new recruitment methods.

Promising data warehousing systems like Janus are still waiting to realize their potential.

Global research in children affects industry and the trial environment.

Plan ahead for many seasonal diseases that could derail even the best laid clinical trials.

While it has yet to be fully integrated, electronic data capture is gaining ground in Japan.

Economical development and regulatory standards make the country a logical choice for trials.

With a PC and some software you can generate realistic projections that save time and money.

The once recession-proof industry must now seek out opportunities to defend itself from potential downfalls.

Evolving out of disconnected technology solutions and working toward integrated processes.

Alleviating clinical trial costs in two pivotal areas with the use of collaborative technology.

A look at how the current financial crisis has established more opportunity for the contract research organization industry.

Today's drug sponsors need to prepare and practice for worst-case clinical trial scenarios.

Using predictive modeling to combat the challenges of study enrollment.

Undertaking clinical studies in this emerging region requires first overcoming natural barriers.

Knowing what you want from a CROs proposal will help make the most of the selection process.

With so much depending on accurate data, taking a do-it-yourself approach to scoring can be risky.

An integrated product development plan designed early increases the odds of on time success.

Improving the quality of radiological measurements in oncology trials with IAs.

Out of necessity, providers may finally become valued strategic partners.